NEW YORK (GenomeWeb) – Horizon Discovery today announced it has signed an OEM agreement to sell its Horizon Diagnostics reference materials alongside ArcherDx's Archer FusionPlex ALK fusion assays, to aid customer validation of the kits.

Horizon said that its HDx reference materials offer a high-quality, sustainable source of independent external controls to laboratories and manufacturers, and include standards for the increasing number of rare mutations being targeted for cancer therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.